Safety and Efficacy of Barzolvolimab, an Anti-KIT Monoclonal Antibody, in Adults With Moderate-to-Severe Prurigo Nodularis: A Randomized Phase 1b Intravenous Single Dose Study.
Document Type
Article
Publication Date
12-2025
Publication Title
Journal of the American Academy of Dermatology
Volume
93
Issue
6
First Page
1596
Last Page
1599
Recommended Citation
Metz M, Ständer S, Moiin A, Nattkemper L, Bloom B, Alvarado D, et al. Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: a randomized phase 1b intravenous single dose study. J Am Acad Dermatol. 2025 Dec;93(6):1596-1599. doi: 10.1016/j.jaad.2025.08.022. PMID: 40840687.
DOI
10.1016/j.jaad.2025.08.022
ISSN
1097-6787
PubMed ID
40840687
COinS